A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION

被引:1053
作者
BELLGRAU, D
GOLD, D
SELAWRY, H
MOORE, J
FRANZUSOFF, A
DUKE, RC
机构
[1] UNIV COLORADO,SCH MED,DEPT IMMUNOL,DENVER,CO 80262
[2] UNIV COLORADO,SCH MED,BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO 80262
[3] UNIV COLORADO,SCH MED,DEPT CELLULAR & STRUCT BIOL,DENVER,CO 80262
[4] UNIV COLORADO,SCH MED,DEPT MED,DIV MED ONCOL,DENVER,CO 80262
[5] SIDNEY KIMMEL CANC CTR,SAN DIEGO,CA 92121
[6] VET ADM MED CTR,MEMPHIS,TN 38104
关键词
D O I
10.1038/377630a0
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
TESTIS is a remarkable immune-privileged site, long known for its ability to support allogeneic and xenogeneic tissue transplants(1-4). Here we have investigated the molecular basis for testis immune privilege. Testis grafts derived from mice that can express functional CD95 (Fas or Ape-1) ligand(5-8) survived indefinitely when transplanted under the kidney capsule of allogeneic animals, whereas testis grafts derived from mutant gld mice, which express non-functional ligands(8,9), were rejected. Further analysis of testis showed that CD95 ligand messenger RNA is constitutively expressed by testicular Sertoli cells, and that Sertoli cells from normal mice, but not gld mice, were accepted when transplanted into allogeneic recipients. CD95 ligand expression in the testis probably acts by inducing apoptotic cell death of CD95-expressing, recipient T cells activated in response to graft antigens. These findings indicate that CD95 ligand could be used to create immune-privileged tissue for a variety of transplant uses.
引用
收藏
页码:630 / 632
页数:3
相关论文
共 30 条
[1]  
BARKER CF, 1977, ADV IMMUNOL, V25, P1
[2]   INTRATESTICULAR TRANSPLANTS OF ISLET XENOGRAFTS (RAT TO MOUSE) [J].
BOBZIEN, B ;
YASUNAMI, Y ;
MAJERCIK, M ;
LACY, PE ;
DAVIE, JM .
DIABETES, 1983, 32 (03) :213-216
[3]   CELL-AUTONOMOUS FAS (CD95) FAS-LIGAND INTERACTION MEDIATES ACTIVATION-INDUCED APOPTOSIS IN T-CELL HYBRIDOMAS [J].
BRUNNER, T ;
MOGIL, RJ ;
LAFACE, D ;
YOO, NJ ;
MAHBOUBI, A ;
ECHEVERRI, F ;
MARTIN, SJ ;
FORCE, WR ;
LYNCH, DH ;
WARE, CF ;
GREEN, DR .
NATURE, 1995, 373 (6513) :441-444
[4]   SUCCESSFUL ISLET ABDOMINAL TESTIS TRANSPLANTATION DOES NOT REQUIRE LEYDIG-CELLS [J].
CAMERON, DF ;
WHITTINGTON, K ;
SCHULTZ, RE ;
SELAWRY, HP .
TRANSPLANTATION, 1990, 50 (04) :649-653
[5]   THE LPR AND GLD GENES IN SYSTEMIC AUTOIMMUNITY - LIFE AND DEATH IN THE FAS LANE [J].
COHEN, PL ;
EISENBERG, RA .
IMMUNOLOGY TODAY, 1992, 13 (11) :427-428
[6]   AUTOCRINE T-CELL SUICIDE MEDIATED BY APO-1/(FAS/CD95) [J].
DHEIN, J ;
WALCZAK, H ;
BAUMLER, C ;
DEBATIN, KM ;
KRAMMER, PH .
NATURE, 1995, 373 (6513) :438-441
[7]   ROLE OF LYMPHOKINE IN ISLET ALLOGRAFT-REJECTION [J].
HAO, LM ;
WANG, Y ;
GILL, RG ;
LAROSA, FG ;
TALMAGE, DW ;
LAFFERTY, KJ .
TRANSPLANTATION, 1990, 49 (03) :609-614
[8]   FAS(CD95) FASL INTERACTIONS REQUIRED FOR PROGRAMMED CELL-DEATH AFTER T-CELL ACTIVATION [J].
JU, ST ;
PANKA, DJ ;
CUI, HL ;
ETTINGER, R ;
ELKHATIB, M ;
SHERR, DH ;
STANGER, BZ ;
MARSHAKROTHSTEIN, A .
NATURE, 1995, 373 (6513) :444-448
[9]   PARTICIPATION OF TARGET FAS PROTEIN IN APOPTOSIS PATHWAY INDUCED BY CD4(+) TH1 AND CD8(+) CYTOTOXIC T-CELLS [J].
JU, ST ;
CUI, HL ;
PANKA, DJ ;
ETTINGER, R ;
MARSHAKROTHSTEIN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (10) :4185-4189
[10]   FAS-BASED D10S-MEDIATED CYTOTOXICITY REQUIRES MACROMOLECULAR-SYNTHESIS FOR EFFECTOR CELL ACTIVATION BUT NOT FOR TARGET-CELL DEATH [J].
LUCIANI, MF ;
GOLSTEIN, P .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1994, 345 (1313) :303-309